Metastatic Castration-resistant Prostate Cancer
Conditions
Keywords
Prostate cancer, Docetaxel, Wnt pathway, Cirmtuzumab, ROR1
Brief summary
The purpose of this study is to examine the safety and efficacy of cirmtuzumab in combination with standard of care docetaxel in patients with metastatic castration resistant prostate cancer. Docetaxel is a taxane chemotherapy which has been shown to prolong survival in men with castration resistant prostate cancer. Cirmtuzumab is a monoclonal antibody that targets the receptor called ROR1 of the non-canonical Wnt pathway and is suspected to contribute to prostate cancer growth and progression.
Detailed description
This study seeks to targeting the non-canonical Wnt pathway with an antibody against ROR1. ROR1 is an attractive target given its low expression in non-malignant tissues and its role in proliferation and survival in prostate cancer. From preclinical data in a variety of tumor types, blockade of ROR1 inhibits cell growth and cirmtuzumab has shown efficacy in clinical trials with CLL. Preclinical data suggests that ROR1 is upregulated in chemotherapy resistant cells and treatment with cirmtuzumab and a taxane achieved higher cytotoxic response than both agents alone, supporting the use of the combination of cirmtuzumab and a taxane. Based on the biological rationale behind cirmtuzumab and preclinical activity with docetaxel, this is an open label, phase 2 clinical trial to evaluate the safety and efficacy of cirmtuzumab in combination with docetaxel for the treatment of metastatic, castrate resistant prostate adenocarcinoma.
Interventions
DRUGCirmtuzumab
Cirmtuzumab will be given in combination with docetaxel.
Sponsors
University of California, San Diego
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Participants must have histologically or cytologically confirmed adenocarcinoma of the prostate. Patients with neuroendocrine component are eligible. 2. Participants must have castrate levels of serum testosterone \< 50 ng/dL. 3. Participants without orchiectomy must be maintained on luteinizing hormone releasing hormone (LHRH) agonist/antagonist. 4. Participants must have received prior abiraterone and/or next generation androgen receptor antagonist (enzalutamide, apalutamide, or darolutamide) for hormone sensitive disease or CRPC. Prior docetaxel for hormone sensitive disease is permitted. 5. Participants must have progressive disease. Patients with non-measurable disease are eligible. 6. Eastern Cooperative Oncology Group performance status ≤1 (Karnofsky ≥80%). 7. Patients must have normal organ and marrow function.
Exclusion criteria
1. No pure small cell carcinoma. 2. Prior treatment with cirmtuzumab. 3. No prior treatment with docetaxel for CRPC. 4. Treatment with abiraterone, apalutamide, or darolutamide within 2 weeks of treatment initiation. Treatment with cytotoxic chemotherapy within 3 weeks of treatment initiation. Treatment enzalutamide or other investigational prostate cancer directed therapy within 4 weeks of treatment initiation. 5. Palliative radiation therapy to the bone or other sites within 2 weeks of treatment initiation. 6. Imminent or established spinal cord compression based on clinical and/or imaging findings. 7. Known active central nervous system metastases and/or carcinomatous meningitis. 8. Uncontrolled intercurrent illness or clinically significant medical condition. 9. Treatment with antimicrobial agent within 4 weeks of treatment initiation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recommended phase 2 dose of docetaxel combined with cirmtuzumab | Patients will be followed from study entry to death or date last known alive, assessed up to 36 months | Defined by CTCAE version 5 grading |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Total alkaline phosphatase response | Patients will be followed from study entry to death or date last known alive, assessed up to 36 months | Defined as a reduction of ≥30% from the baseline value, confirmed ≥4 weeks later. |
| Time to PSA progression | Patients will be followed from study entry to death or date last known alive, assessed up to 36 months | Defined by PCWG-3 criteria |
| Time to increase in the total alkaline phosphatase level | Patients will be followed from study entry to death or date last known alive, assessed up to 36 months | Defined as an increase of ≥25% from baseline at ≥12 weeks, in patients with no decrease from baseline, or as an increase of ≥25% above the nadir, confirmed ≥3 weeks later, in patients with an initial decrease from baseline. |
| Radiographic progression free survival | Patients will be followed from study entry to death or date last known alive, assessed up to 36 months | Defined by PCWG-3 criteria for bone metastases and RECIST version 1.1 for soft tissue |
| Incidence of treatment-emergent adverse events | Patients will be followed from study entry to death or date last known alive, assessed up to 36 months | Defined by CTCAE version 5 grading |
| Time to first symptomatic skeletal event | Patients will be followed from study entry to death or date last known alive, assessed up to 36 months | Time to first symptomatic pathologic fracture, radiation to the bone given symptomatic bone metastasis, surgery to the bone given symptomatic bone metastasis, or symptomatic spinal cord compression |
| Overall survival | Patients will be followed from study entry to death or date last known alive, assessed up to 36 months | Time from enrollment to death or last follow up |
| Composite clinical benefit | Patients will be followed from study entry to death or date last known alive, assessed up to 36 months | Composite endpoint of clinical benefit defined as any one of the following: PSA response by PCWG3 criteria, objective response rate by RECIST version 1.1, and stable disease \> 6 months by RECIST version 1.1. |
| Time to first subsequent anti-cancer therapy | Patients will be followed from study entry to death or date last known alive, assessed up to 36 months | Time from study discontinuation to initiation of subsequent systemic anti-cancer therapy or death |
Countries
United States
Outcome results
None listed